210 related articles for article (PubMed ID: 35947351)
1. A Systematic Review, Meta-Analysis, and Indirect Comparison of Blindly Adjudicated Cardiovascular Event Incidence with Ferric Derisomaltose, Ferric Carboxymaltose, and Iron Sucrose.
Pollock RF; Kalra PA; Kalra PR; Ahmed FZ
Adv Ther; 2022 Oct; 39(10):4678-4691. PubMed ID: 35947351
[TBL] [Abstract][Full Text] [Related]
2. Cost-utility analysis of ferric derisomaltose versus ferric carboxymaltose in patients with inflammatory bowel disease and iron deficiency anemia in England.
Iqbal TH; Kennedy N; Dhar A; Ahmed W; Pollock RF
J Med Econ; 2024; 27(1):392-403. PubMed ID: 38391240
[TBL] [Abstract][Full Text] [Related]
3. Incidence of Hypophosphatemia After Intravenous Administration of Iron: A Matching-Adjusted Indirect Comparison of Data from Japanese Randomized Controlled Trials.
Fukumoto S; Murata T; Osuga Y; Pollock RF
Adv Ther; 2023 Nov; 40(11):4877-4888. PubMed ID: 37702931
[TBL] [Abstract][Full Text] [Related]
4. Indirect methods of comparison of the safety of ferric derisomaltose, iron sucrose and ferric carboxymaltose in the treatment of iron deficiency anemia.
Pollock RF; Biggar P
Expert Rev Hematol; 2020 Feb; 13(2):187-195. PubMed ID: 31928094
[No Abstract] [Full Text] [Related]
5. Intravenous iron for the treatment of iron deficiency anemia in China: a patient-level simulation model and cost-utility analysis comparing ferric derisomaltose with iron sucrose.
Hu S; Liu L; Pollock RF; Pöhlmann J; Wu D; Zhang Y
J Med Econ; 2022; 25(1):561-570. PubMed ID: 35403540
[TBL] [Abstract][Full Text] [Related]
6. Comparative efficacy and safety of intravenous ferric carboxymaltose and iron sucrose for iron deficiency anemia in obstetric and gynecologic patients: A systematic review and meta-analysis.
Shin HW; Go DY; Lee SW; Choi YJ; Ko EJ; You HS; Jang YK
Medicine (Baltimore); 2021 May; 100(20):e24571. PubMed ID: 34011020
[TBL] [Abstract][Full Text] [Related]
7. A systematic literature review and meta-analysis of the incidence of serious or severe hypersensitivity reactions after administration of ferric derisomaltose or ferric carboxymaltose.
Kennedy NA; Achebe MM; Biggar P; Pöhlmann J; Pollock RF
Int J Clin Pharm; 2023 Jun; 45(3):604-612. PubMed ID: 37010731
[TBL] [Abstract][Full Text] [Related]
8. A systematic literature review and indirect comparison of iron isomaltoside and ferric carboxymaltose in iron deficiency anemia after failure or intolerance of oral iron treatment.
Pollock RF; Muduma G
Expert Rev Hematol; 2019 Feb; 12(2):129-136. PubMed ID: 30689458
[TBL] [Abstract][Full Text] [Related]
9. Hypophosphatemia after high-dose iron repletion with ferric carboxymaltose and ferric derisomaltose-the randomized controlled HOMe aFers study.
Emrich IE; Lizzi F; Siegel JD; Seiler-Mussler S; Ukena C; Kaddu-Mulindwa D; D'Amelio R; Wagenpfeil S; Brandenburg VM; Böhm M; Fliser D; Heine GH
BMC Med; 2020 Jul; 18(1):178. PubMed ID: 32654663
[TBL] [Abstract][Full Text] [Related]
10. Comparison of efficacy and safety between intravenous ferric carboxymaltose and saccharated ferric oxide in Japanese patients with iron-deficiency anemia due to hypermenorrhea: a multi-center, randomized, open-label noninferiority study.
Ikuta K; Hanashi H; Hirai K; Ota Y; Matsuyama Y; Shimura A; Terauchi M; Momoeda M
Int J Hematol; 2019 Jan; 109(1):41-49. PubMed ID: 30039442
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of ferric derisomaltose (FDI) compared with iron sucrose (IS) in patients with iron deficiency anemia after bariatric surgery.
Auerbach M; Achebe MM; Thomsen LL; Derman RJ
Obes Surg; 2022 Mar; 32(3):810-818. PubMed ID: 35000068
[TBL] [Abstract][Full Text] [Related]
12. Ferric carboxymaltose in patients with iron-deficiency anemia and impaired renal function: the REPAIR-IDA trial.
Onken JE; Bregman DB; Harrington RA; Morris D; Buerkert J; Hamerski D; Iftikhar H; Mangoo-Karim R; Martin ER; Martinez CO; Newman GE; Qunibi WY; Ross DL; Singh B; Smith MT; Butcher A; Koch TA; Goodnough LT
Nephrol Dial Transplant; 2014 Apr; 29(4):833-42. PubMed ID: 23963731
[TBL] [Abstract][Full Text] [Related]
13. A multicenter, randomized, active-controlled study to investigate the efficacy and safety of intravenous ferric carboxymaltose in patients with iron deficiency anemia.
Onken JE; Bregman DB; Harrington RA; Morris D; Acs P; Akright B; Barish C; Bhaskar BS; Smith-Nguyen GN; Butcher A; Koch TA; Goodnough LT
Transfusion; 2014 Feb; 54(2):306-15. PubMed ID: 23772856
[TBL] [Abstract][Full Text] [Related]
14. Randomized evaluation of efficacy and safety of ferric carboxymaltose in patients with iron deficiency anaemia and impaired renal function (REPAIR-IDA): rationale and study design.
Szczech LA; Bregman DB; Harrington RA; Morris D; Butcher A; Koch TA; Goodnough LT; Wolf M; Onken JE
Nephrol Dial Transplant; 2010 Jul; 25(7):2368-75. PubMed ID: 20466657
[TBL] [Abstract][Full Text] [Related]
15. The differential effect of modern intravenous iron on fibroblast growth factor 23 and phosphate in non-dialysis dependent CKD - the exploratory randomized controlled double-blind ExplorIRON-CKD study.
Kassianides X; Bhandari S
BMC Nephrol; 2024 Feb; 25(1):54. PubMed ID: 38347520
[TBL] [Abstract][Full Text] [Related]
16. Safety and efficacy of intravenous iron polymaltose, iron sucrose and ferric carboxymaltose in pregnancy: A systematic review.
Qassim A; Mol BW; Grivell RM; Grzeskowiak LE
Aust N Z J Obstet Gynaecol; 2018 Feb; 58(1):22-39. PubMed ID: 28921558
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of intravenous iron repletion in patients with heart failure: a systematic review and meta-analysis.
Vukadinović D; Abdin A; Emrich I; Schulze PC; von Haehling S; Böhm M
Clin Res Cardiol; 2023 Jul; 112(7):954-966. PubMed ID: 37074386
[TBL] [Abstract][Full Text] [Related]
18. A patient-level cost-effectiveness analysis of iron isomaltoside versus ferric carboxymaltose for the treatment of iron deficiency anemia in the United Kingdom.
Pollock RF; Muduma G
J Med Econ; 2020 Jul; 23(7):751-759. PubMed ID: 32208038
[No Abstract] [Full Text] [Related]
19. The Efficacy, Safety, and Economic Outcomes of Using Ferric Derisomaltose for the Management of Iron Deficiency in China: A Rapid Health Technology Assessment.
Yun L; YuMei Z; Bn V; Tang Q; Feng C
Cureus; 2023 Nov; 15(11):e48717. PubMed ID: 38094535
[TBL] [Abstract][Full Text] [Related]
20. Clinical effectiveness of ferric carboxymaltose (iv) versus iron sucrose (iv) in treatment of iron deficiency anaemia in pregnancy: A systematic review and meta-analysis.
Srimathi G; Revathy R; Bagepally BS; Joshi B
Indian J Med Res; 2024 Jan; 159(1):62-70. PubMed ID: 38439125
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]